comparemela.com

Latest Breaking News On - Larimar therapeutics inc - Page 1 : comparemela.com

Larimar Therapeutics (NASDAQ:LRMR) Shares Gap Up to $7.10

Larimar Therapeutics (NASDAQ:LRMR) Shares Gap Up to $7.10
theenterpriseleader.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from theenterpriseleader.com Daily Mail and Mail on Sunday newspapers.

Alger
Algeria
Leerink-partnrs
Entrypoint-capital
Citigroup
Sg-americas-securities
Larimar-therapeutics-inc
Nasdaq
Virtu-financial
Fred-alger-management
Larimar-therapeutics
Get-free-report

Why SentinelOne Shares Are Trading Lower By 16%? Here Are Other Stocks Moving In Friday's Mid-Day Session - AC Immune (NASDAQ:ACIU), Adaptimmune Therapeutics (NASDAQ:ADAP)

Why SentinelOne Shares Are Trading Lower By 16%? Here Are Other Stocks Moving In Friday's Mid-Day Session - AC Immune (NASDAQ:ACIU), Adaptimmune Therapeutics (NASDAQ:ADAP)
benzinga.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from benzinga.com Daily Mail and Mail on Sunday newspapers.

Onemednet-corporation
Fitell-corporation
Ttec-inc
Thomas-shrader
Calidi-biotherapeutics-inc
Michelle-choehas
Donald-trump
Master-services-agreement
Sentinelone-inc
Hp-inc
Brand-engagement-network-inc
Novo-integrated-sciences-inc

Brokerages Set Larimar Therapeutics, Inc. (NASDAQ:LRMR) Price Target at $21.33

Larimar Therapeutics, Inc. (NASDAQ:LRMR – Get Free Report) has earned a consensus recommendation of “Buy” from the six analysts that are covering the company, Marketbeat.com reports. Six investment analysts have rated the stock with a buy recommendation. The average twelve-month price objective among brokers that have updated their coverage on the stock in the last […]

Alger
Algeria
Leerink-partnrs
Larimar-therapeutics-inc
Sg-americas-securities
Fred-alger-management
Entrypoint-capital
Nasdaq
Citigroup
Virtu-financial
Larimar-therapeutics
Get-free-report

Larimar Therapeutics (NASDAQ:LRMR) Receives Market Outperform Rating from JMP Securities

JMP Securities reaffirmed their market outperform rating on shares of Larimar Therapeutics (NASDAQ:LRMR – Free Report) in a report released on Tuesday, Benzinga reports. They currently have a $25.00 price objective on the stock. Several other brokerages also recently commented on LRMR. Citigroup increased their price objective on Larimar Therapeutics from $4.50 to $10.00 and […]

Alger
Algeria
Leerink-partnrs
Entrypoint-capital
Larimar-therapeutics-inc
Citigroup
Virtu-financial
Sg-americas-securities
Larimar-therapeutics-company-profile
Fred-alger-management
Larimar-therapeutics
Free-report

vimarsana © 2020. All Rights Reserved.